While median TIS scores are higher in tumor types with higher rates of response to PD-1/PD-L1 inhibitors (e.g., melanoma, renal cell cancer), and cancers with high mutation load (e.g., non-small cell lung cancer [NSCLC]), within each tumor type there is considerable inter-sample variability. The gene discussed is PDCD1; the disease is cancer.